Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Neoplasms 3Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Glioma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphoid 1Gliosarcoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × enzastaurin × Clear all
NCT00420381 2020-12-19

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

Eli Lilly and Company

Phase 2 Completed
28 enrolled 13 charts
Gynecologic

Carcinoma, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡